EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Botulinum toxin type A for gummy smile

Diego Silva

Journal of Digital Health and Advanced Biomaterials · 24.03.2026 · 1 (1) · 5-13

DOI: 10.67463/2pcxgv61 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Digital Health and Advanced Biomaterials, online erschienen am 24.03.2026. Verfasst von Diego Silva. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To critically reassess the use of botulinum toxin type A (BoNT/A) for gummy smile, with emphasis on anatomical targeting, protocol variability, and the conditions required for reproducible outcome measurement.Data sources: Literature addressing etiologic phenotyping of gummy smile, elevator-muscle anatomy, BoNT/A formulation and preparation, targeted clinical application, and digital approaches to image-based outcome capture.Eligibility criteria: Studies and technical sources were prioritized when they directly informed five linked domains: phenotype selection, anatomical rationale, product handling, delivery variables, and the reliability of endpoint documentation.Methods of synthesis: Critical narrative review integrating anatomical, clinical, pharmaceutical, and measurement-oriented evidence relevant to the translational interpretation of BoNT/A therapy for gummy smile.Main findings: The literature supports temporary gingival-display reduction in selected muscular cases and offers a credible anatomical rationale for targeting the Yonsei region. However, universality of the point is not supported. Morphometric variation, heterogeneous smile-task architecture, non-equivalent product preparation, and incompletely reported dose-volume-depth relationships remain major interpretive barriers.

Conclusion

BoNT/A remains a defensible minimally invasive option for compatible muscular etiologies, but the field will mature only when anatomical targeting, product handling, dose-volume-depth architecture, smile-task definition, and digitally auditable outcome measurement are integrated within one reproducible protocol.

Zitieren

APA

Silva, D. (2026). Botulinum toxin type A for gummy smile. Journal of Digital Health and Advanced Biomaterials, 1(1), 5-13. https://doi.org/10.67463/2pcxgv61

Vancouver

Silva D. Botulinum toxin type A for gummy smile. Journal of Digital Health and Advanced Biomaterials. 2026;1(1):5-13. doi:10.67463/2pcxgv61

BibTeX
@article{Silva2026,
  author = {Silva, Diego},
  title = {Botulinum toxin type A for gummy smile},
  journal = {Journal of Digital Health and Advanced Biomaterials},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {5--13},
  doi = {10.67463/2pcxgv61}
}
Kostenlos starten →